2.58

28.33% -1.02

After Hours: 2.62 0.04 +1.55%

Polaryx Therapeutics Inc (PLYX)

Overview News Price History Discussions Forecast

Polaryx Therapeutics Inc stock is traded at $2.58, with a volume of 1.21M. It is down -28.33% in the last 24 hours and down -46.80% over the past month. Polaryx Therapeutics Inc is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric LSDs. Its therapeutic approach focuses on treating the underlying pathophysiology of these diseases and addressing unmet needs. The company's therapeutic pipeline includes PLX-200, PLX-300, and PLX-100, which are orally available small-molecule drug candidates designed to address core pathological mechanisms common to LSDs. The Company has one reportable segment: lysosomal storage disorders. The lysosomal storage disorders segment consists of the Company's costs associated with the preclinical and clinical development of the Company's product candidates.

Previous Close:

$3.60

Open:

$3.59

24h Volume:

1.21M

Relative Volume:

1.37

Market Cap:

$122.15M

Revenue:

Net Income/Loss:

$-8.99M

P/E Ratio:

-13.59

EPS:

-0.1898

Net Cash Flow:

$-3.94M

1W Performance:

-15.69%

1M Performance:

-46.80%

6M Performance:

+0.00%

1Y Performance:

+0.00%

1-Day Range:

$2.33

$3.78

1-Week Range:

$2.33

$4.205

52-Week Range:

$2.201

$33.90

Polaryx Therapeutics Inc Stock (PLYX) Company Profile

Name

Polaryx Therapeutics Inc

Sector

Healthcare (1111)

Industry

Biotechnology (621)

Phone

201-940-7236

Address

140 EAST RIDGEWOOD AVENUE, PARAMUS

Employee

Twitter

Next Earnings Date

null

Latest SEC Filings

PLYX's Discussions on Twitter

Compare PLYX vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PLYX Polaryx Therapeutics Inc	2.58	170.44M	0	-8.99M	-3.94M	-0.1898
VRTX Vertex Pharmaceuticals Inc	435.93	110.28B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	634.62	66.98B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	808.43	50.15B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	295.50	39.71B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	154.89	32.22B	742.00K	-1.37B	-1.07B	-7.0731

Polaryx Therapeutics Inc Stock (PLYX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-27-26	Initiated	Maxim Group	Buy

Polaryx Therapeutics Inc Stock (PLYX) Latest News

04:00 AM

PLYX - Finviz

04:00 AM

May 22, 2026

PLYX Technical Analysis | Trend, Signals & Chart Patterns | POLARYX THERAPEUTICS INC (NASDAQ:PLYX) - ChartMill

May 22, 2026

May 15, 2026

Polaryx Therapeutics, Inc. Q1 2026 Financial Results and Pipeline Update: Progress in Rare Pediatric Lysosomal Storage Disorder Therapies - Minichart

May 15, 2026

Polaryx Therapeutics (NASDAQ: PLYX) narrows loss but flags going concern risk - Stock Titan

May 15, 2026

Polaryx Therapeutics 1Q 2026: Net income $(2.54M), EPS $(0.05) — 10-Q Summary - TradingView

May 15, 2026

Polaryx Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com

May 15, 2026

May 14, 2026

Polaryx Therapeutics Awarded Double Honors at the 2026 GHP Healthcare & Pharmaceutical Awards - Quiver Quantitative

May 14, 2026

Polaryx Therapeutics Receives GHP Magazine’s Healthcare & Pharmaceuticals Awards - The Manila Times

May 14, 2026

Biotech for rare pediatric lysosomal diseases wins 2 GHP awards - Stock Titan

May 14, 2026

May 13, 2026

PLYX Stock Price, Quote & Chart | POLARYX THERAPEUTICS INC (NASDAQ:PLYX) - ChartMill

May 13, 2026

May 08, 2026

Number of shareholders of Polaryx Therapeutics, Inc. – NASDAQ:PLYX - TradingView

May 08, 2026

May 07, 2026

PLYX Polaryx Therapeutics highlights rare disease pipeline progress in its newly released quarterly earnings report.Verified Stock Signals - Newser

Apr 24, 2026

Apr 23, 2026

Polaryx Therapeutics to Participate in National Tay-Sachs & Allied Diseases Association Annual Family Conference - The Manila Times

Apr 23, 2026

Polaryx heads to Tay-Sachs family meeting with Phase 2 program - Stock Titan

Apr 23, 2026

Apr 22, 2026

FDA grants fast track status to Polaryx’s PLX-200 for three rare diseases - Investing.com Nigeria

Apr 22, 2026

Apr 21, 2026

Polaryx receives U.S. FDA Fast Track Designation for PLX-200 - TipRanks

Apr 21, 2026

Polaryx Therapeutics Gets FDA Fast Track Designations for Its Lead Drug Candidate - marketscreener.com

Apr 21, 2026

Polaryx Therapeutics receives U.S. FDA fast track designations for all four indications to be evaluated in the Soteria Basket Trial - marketscreener.com

Apr 21, 2026

Polaryx Therapeutics Receives U.S. FDA Fast Track Designations for All Four Indications to be Evaluated in the SOTERIA Basket Trial - The Manila Times

Apr 21, 2026

FDA fast-tracks Polaryx drug for 4 rare childhood disorders - Stock Titan

Apr 21, 2026

Apr 20, 2026

Does Polaryx Therapeutics (PLYX) Stock Pay Dividends? (Underperforming) 2026-04-20Real Trader Network - Cổng thông tin điện tử Tỉnh Sơn La

Apr 20, 2026

Apr 17, 2026

PLYX Should I Buy - Intellectia AI

Apr 17, 2026

Apr 15, 2026

Polaryx Therapeutics Recognized with Pinnacle Award for Excellence in Pediatric Care - The Manila Times

Apr 15, 2026

A rare-disease biotech, Polaryx, just won a pediatric care award - Stock Titan

Apr 15, 2026

Apr 14, 2026

Number of employees of Polaryx Therapeutics, Inc. – NASDAQ:PLYX - TradingView

Apr 14, 2026

Apr 10, 2026

What makes Polaryx Therapeutics (PLYX) Stock attractive or not | Price at $5.63, Down 2.26%Breakout Watch - Cổng thông tin điện tử tỉnh Lào Cai

Apr 10, 2026

Apr 09, 2026

PLYX Stock Price and Chart — NASDAQ:PLYX - TradingView

Apr 09, 2026

Apr 08, 2026

Polaryx Therapeutics, Inc.Common Stock (NQ: PLYX - The Chronicle-Journal

Apr 08, 2026

Apr 07, 2026

Polaryx Therapeutics, Inc. News — NASDAQ:PLYX - TradingView

Apr 07, 2026

Apr 06, 2026

12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga

Apr 06, 2026

Apr 02, 2026